BillionToOne (BLLN) Q3 2025 earnings review
Hypergrowth Meets Profitability
BillionToOne delivered a breakout quarter, proving it can scale rapidly while turning a profit. Revenue surged 117% YoY to $83.5M, driven by a rare combination of volume growth (+52%) and pricing power (ASP +44%). Crucially, the company swung from a $12.6M operating loss a year ago to a $9.6M profit, validated by a massive gross margin expansion to 70%. With the Oncology segment growing nearly 8x and a fresh $314M IPO capital injection, BLLN has successfully pivoted from 'cash-burning growth' to 'profitable scaling.'
🐂 Bull Case
It is rare to see volume (+52%) and price (+44%) surge simultaneously. ASPs hit $501 (up from $348), driving a 1700bps gross margin expansion to 70%. The technology is commanding premium reimbursement.
While Prenatal pays the bills, Oncology is the rocket fuel. Segment revenue grew 664% YoY and 76% sequentially vs Q2. It is rapidly becoming a material contributor ($8.7M).
🐻 Bear Case
Despite triple-digit YoY growth, Q4 guidance ($84-90M) implies flat-to-low single-digit sequential growth vs Q3 ($83.5M). The explosive momentum may be taking a breather.
Prenatal testing still accounts for ~89% of total revenue ($74.1M). Any regulatory shift or reimbursement pushback in this specific vertical would derail the entire financial model.
⚖️ Verdict: 🟢🟢
Strong Bull. Triple-digit growth accompanied by a swing to GAAP profitability is the 'holy grail' for diagnostics companies. The 70% gross margin profile validates the tech stack's scalability.
Key Themes
Margin Structure Transformation
Accelerating. Gross margin exploded from 53% in 24Q3 to 70% in 25Q3. This was not just cost-cutting; it was driven by higher ASPs ($501 vs $348) and efficiencies in the molecular counting platform. This margin profile creates a clear path to sustained free cash flow.
Oncology Segment Breakout
Accelerating. Oncology revenue reached $8.7M, up 664% YoY and—more importantly—up 76% sequentially from $4.9M in Q2. This segment validates the platform beyond prenatal care and offers a much larger TAM. The 'Response' and 'Select' tests are gaining rapid traction.
Unit Economics: Volume and Price
Stable/Accelerating. Total tests delivered rose 52% to 165,000. Usually, scaling volume dilutes price. Instead, Overall ASP jumped 44% to $501. This indicates improved payer mix, better reimbursement collection, or a shift to higher-value tests.
Sequential Revenue Flattening
Decelerating. While YoY numbers are massive, the sequential trend warrants caution. Q3 revenue was $83.5M. The midpoint of Q4 guidance is $87M. This implies only ~4% sequential growth, a significant cooldown from the pace seen earlier in the year. Management may be sandbagging, or capacity/seasonality is kicking in.
Prenatal Reliance
Stable. Prenatal revenue was $74.1M, accounting for 89% of total sales. While Oncology is growing faster, the company effectively remains a single-segment story today. Any reimbursement headwinds in the NIPT space would immediately impact the P&L.
Accounts Receivable Build
Accounts Receivable rose to $34.6M from $24.7M at year-end '24. While revenue has grown faster, managing collections as ASPs rise is critical. A spike in AR often precedes reimbursement disputes in the diagnostics sector.
Fortress Balance Sheet Post-IPO
Ending Q3 with $195M in cash + raising ~$286M net from the Nov IPO puts pro-forma cash near $480M. With positive operating cash flow ($6.2M in Q3), dilution risk is effectively zero for the foreseeable future.
Other KPIs
Reversing. A massive swing from a $12.6M loss in the prior year. Operating margin hit 11.5%. Management expects to remain profitable in Q4 and FY25, confirming the business model has crossed the breakeven threshold.
Reversing. Positive cash flow generation means the company is self-sustaining operationally, making the IPO proceeds pure growth capital rather than a lifeline.
Stable growth. Up 35% YoY vs Revenue growth of 117%. This demonstrates operating leverage—innovation costs are growing much slower than the topline.
Guidance
Decelerating sequential momentum. Represents 86-100% YoY growth, but the sequential bump from Q3 ($83.5M) is minimal at the low end. Likely reflects conservatism or holiday seasonality impact on testing volumes.
Accelerating. Implies 92-96% annual growth. This confirms the company will nearly double its size this year.
Stable. Reaffirms the Q3 breakout wasn't a fluke. Expects positive GAAP operating income for both Q4 and the full year.
Key Questions
ASP Sustainability
ASPs jumped 44% YoY to $501. Was this driven by a one-time true-up/collection event, or is this the new structural baseline for pricing given your mix shift?
Oncology Sales Ramp
Oncology grew 76% sequentially. Can you detail the sales force expansion plan for this segment in 2026? Are you seeing any lengthening of sales cycles as you move up-market?
Q4 Conservatism
Your Q4 guidance implies flat-to-low single digit sequential growth despite massive YoY numbers. Are you seeing a slowdown in accession volume entering the holiday season, or is this purely conservatism?
Competitive Response
With Prenatal margins hitting 70%+, are you seeing increased discounting or aggressive behavior from legacy incumbents in the NIPT space?